SPLISENSE
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
SPLISENSE
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2016-01-01
Address:
Jerusalem, Yerushalayim, Israel
Country:
Israel
Website Url:
http://www.splisense.com
Total Employee:
11+
Status:
Active
Total Funding:
28.5 M USD
Technology used in webpage:
Euro Google Maps UPress
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Castle Creek Biosciences
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Q-State Biosciences
Q-State has developed world-leading technologies and proprietary approaches for probing rare and genetic CNS conditions.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Current Advisors List
Current Employees Featured
Founder
Investors List
Biotel
Biotel investment in Series B - Splisense
Integra Holdings
Integra Holdings investment in Series B - Splisense
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Series B - Splisense
Israel Biotech Fund
Israel Biotech Fund investment in Series B - Splisense
OrbiMed
OrbiMed investment in Series B - Splisense
Integra Holdings
Integra Holdings investment in Seed Round - Splisense
Official Site Inspections
http://www.splisense.com
- Host name: s-vps-il-124.upress.io
- IP address: 88.218.116.68
- Location: Rehovot Israel
- Latitude: 31.8943
- Longitude: 34.8192
- Timezone: Asia/Jerusalem
More informations about "Splisense"
Who We Are - splisense.com
SpliSense is a clinical stage company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of pulmonary diseases. Using an innovative approach, …See details»
Splisense - Crunchbase Company Profile & Funding
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.See details»
SpliSense - LinkedIn
SpliSense Ltd., is a growing and exciting biotechnology company, developing novel therapies for genetic diseases by inhalation. The company is currently focusing on splicing mutations in the …See details»
Splisense – Integra Holdings
At a glance Splisense is targeting the Root Cause of Genetic and Pulmonary Diseases. Positioned as a clinical stage company, Splisense is developing a transformative RNA-based …See details»
SpliSense - Israeli Startup | Startup Nation Finder
Jan 4, 2022 SpliSense is a clinical stage company developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases. Its treatment is based on …See details»
Splisense - The Org
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung …See details»
SpliSense 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for SpliSense. Use the PitchBook Platform to explore the full profile.See details»
Home Transformative RNA Based Treatments | splisense.com
Transformative RNA Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Pulmonary Diseases Our innovative RNA based therapies, based on Antisense …See details»
SpliSense | Digital Health Corporate Profiles | HealthTech Alpha
SpliSense is a Pharmaceutical focused corporation. Discover Digital Health profiles, team, funding and valuation with HealthTech Alpha.See details»
SpliSense Overview | SignalHire Company Profile
Organization Website splisense.com Social Links Phone Number 972-52-836-77-31 SpliSense industries Biotech, Biotechnology, Pharmaceuticals Headquarters Location The Hebrew …See details»
RNA Based Platform for Pulmonary Diseases - splisense.com
SpliSense Tackles the Key Challenges of Lung Delivery SPL ASOs are Designed for Optimal Pulmonary Delivery and Target Modulation SPL ASOs are designed and optimized using …See details»
Splisense - Contacts, Employees, Board Members, Advisors & Alumni
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.See details»
SpliSense - Israeli Startup | Startup Nation Finder
Oct 29, 2024 SpliSense Announces FDA and EMA Grant Orphan Drug Designation to SPL84-23-1 for the Treatment of Cystic Fibrosis Israeli firm SpliSense moves to clinical trials for cystic …See details»
Our Platform - splisense.com
The SpliSense platform consists of 4 modalities thatenable the generation of specific ASOs, targeting pulmonary diseases.See details»
Splisense - Funding, Financials, Valuation & Investors
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.See details»
Series B - Splisense - 2021-05-13 - Crunchbase Funding Round …
May 13, 2021 Overview Organization Name Splisense Announced Date May 13, 2021 Funding Type Series B Funding Stage Early Stage Venture Money Raised obfuscatedSee details»
Israeli firm SpliSense moves to trials for cystic fibrosis treatment ...
Jan 4, 2022 Many of the untreated patients are represented by the Cystic Fibrosis Foundation, a nonprofit organization in the US established to promote the development of a cure for cystic …See details»
CF Foundation Invests Up to $8.4M in SpliSense for the …
May 13, 2021 Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy …See details»
Pipeline - splisense.com
SpliSense’s Diverse Pulmonary PipelineSee details»
Press Releases - SpliSense
SpliSense is excited to share its most recent press release, announcing the successful completion a first-in-human, Phase 1 clinical trial of SPL84, the company’s lead anti sense oligonucleotide …See details»